Phospholipase A 2 (PLA 2 ) is the key enzyme that initiates the arachidonic acid cascade, which leads to the generation of multiple eicosanoid products. Many of these products are believed to play an important role in the inflammatory process. Activation of PLA 2 is observed under pathological conditions where inflammation is present. Cytosolic PLA 2 (cPLA 2 ) is activated by very low levels of calcium and is thought to control receptor-mediated eicosanoid production and to participate in intracellular signal transduction processes. In view of the presence of numerous inflammatory mediators and acute phase proteins in the Alzheimer's disease (AD) brain, localization of cPLA 2 in AD brain was evaluated and compared to that observed in nonneurologically diseased controls. In this study, a monoclonal antibody raised against cPLA 2 was used to immunostain tissue sections of human cerebral cortex. Five AD cases and six neurologically normal cases were evaluated in the occipital cortex and the cerebellum. Two of the AD cases were also examined in other cortical regions. Granular-like staining with anti-cPLA 2 was found to be associated with astrocytes in the cortex of both control and AD cases. Colocalization with GFAP confirmed that cPLA 2 immunoreactivity is associated almost exclusively with protoplasmic astrocytes. Staining was abolished when sections were labeled with antibody that had been preadsorbed with purified cPLA 2 . In AD brain, cPLA 2 immunoreactive astrocytes were greater in number and more intensely stained than those in control cases. cPLA 2 immunoreactivity was virtually absent in the cerebellum of AD and control cases, despite the presence in this region of diffuse amyloid in two AD cases and amyloid angiopathy in a third case. In the cortex, cPLA 2 immunoreactive astrocytes were detected in regions that contained numerous Ab deposits. The finding of elevated levels of cPLA 2 immunoreactivity in AD brain supports the hypothesis that there is an active inflammatory process occurring in AD. r
INTRODUCTION
Alzheimer's disease (AD) is characterized clinically by progressive dementia and pathologically by cortical atrophy, neuronal loss, neurofibrillary tangles, senile plaques, and vascular deposits of amyloid-b peptide (Ab) in various regions of the cerebral cortex and the hippocampus. Current evidence clearly indicates that Ab and its precursor amyloid-b precursor protein (b-APP) play a crucial role in the pathogenesis of AD (Selkoe, 1991; Games et al., 1995) . To date, no effective therapy exists for AD patients, and the etiology of this disease remains unknown.
Recent evidence implicates inflammatory and immune mechanisms in the pathogenesis of AD. There is suggestive evidence that treatment of patients with anti-inflammatory agents may be clinically beneficial. Retrospective studies have shown that the prevalence of AD in patients with rheumatoid arthritis is unexpectedly low, which has led to the hypothesis that antiinflammatory medications administered to arthritis patients confer protection against AD (McGeer et al., 1990; Jenkinson et al., 1989) . Recently reported data on
